These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 16874039)

  • 1. p53, Autophagy and tumor suppression.
    Jin S
    Autophagy; 2005; 1(3):171-3. PubMed ID: 16874039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis.
    Chen Z; Trotman LC; Shaffer D; Lin HK; Dotan ZA; Niki M; Koutcher JA; Scher HI; Ludwig T; Gerald W; Cordon-Cardo C; Pandolfi PP
    Nature; 2005 Aug; 436(7051):725-30. PubMed ID: 16079851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The cooperation between p53 and Ras in tumorigenesis].
    Wei YY; Hou J; Tang WR; Luo Y
    Yi Chuan; 2012 Dec; 34(12):1513-21. PubMed ID: 23262097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COP1, the negative regulator of p53, is overexpressed in breast and ovarian adenocarcinomas.
    Dornan D; Bheddah S; Newton K; Ince W; Frantz GD; Dowd P; Koeppen H; Dixit VM; French DM
    Cancer Res; 2004 Oct; 64(20):7226-30. PubMed ID: 15492238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutant p53 expression in fallopian tube epithelium drives cell migration.
    Quartuccio SM; Karthikeyan S; Eddie SL; Lantvit DD; Ó hAinmhire E; Modi DA; Wei JJ; Burdette JE
    Int J Cancer; 2015 Oct; 137(7):1528-38. PubMed ID: 25810107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 regulates Stat3 phosphorylation and DNA binding activity in human prostate cancer cells expressing constitutively active Stat3.
    Lin J; Tang H; Jin X; Jia G; Hsieh JT
    Oncogene; 2002 May; 21(19):3082-8. PubMed ID: 12082540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant expression of BARD1 in breast and ovarian cancers with poor prognosis.
    Wu JY; Vlastos AT; Pelte MF; Caligo MA; Bianco A; Krause KH; Laurent GJ; Irminger-Finger I
    Int J Cancer; 2006 Mar; 118(5):1215-26. PubMed ID: 16152612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding p53: new insights into tumor suppression.
    Kawauchi K; Wolf SJ
    Expert Rev Anticancer Ther; 2014 Oct; 14(10):1101-3. PubMed ID: 25119697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dissecting p53 tumor suppressor function in vivo through the analysis of genetically modified mice.
    Johnson TM; Attardi LD
    Cell Death Differ; 2006 Jun; 13(6):902-8. PubMed ID: 16557272
    [No Abstract]   [Full Text] [Related]  

  • 10. Genetic inhibition of autophagy promotes p53 loss-of-heterozygosity and tumorigenesis.
    Lee E; Wei Y; Zou Z; Tucker K; Rakheja D; Levine B; Amatruda JF
    Oncotarget; 2016 Oct; 7(42):67919-67933. PubMed ID: 27655644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53-Mediated Molecular Control of Autophagy in Tumor Cells.
    Mrakovcic M; Fröhlich LF
    Biomolecules; 2018 Mar; 8(2):. PubMed ID: 29561758
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Ezerskyte M; Paredes JA; Malvezzi S; Burns JA; Margison GP; Olsson M; Scicchitano DA; Dreij K
    Proc Natl Acad Sci U S A; 2018 May; 115(18):4731-4736. PubMed ID: 29666243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 and metabolism.
    Vousden KH; Ryan KM
    Nat Rev Cancer; 2009 Oct; 9(10):691-700. PubMed ID: 19759539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of autophagy and EMT by the interplay between p53 and RAS during cancer progression (Review).
    Zhang X; Cheng Q; Yin H; Yang G
    Int J Oncol; 2017 Jul; 51(1):18-24. PubMed ID: 28560457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of p53 by ING family members in suppression of tumor initiation and progression.
    Jafarnejad SM; Li G
    Cancer Metastasis Rev; 2012 Jun; 31(1-2):55-73. PubMed ID: 22095030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of p53 and suppression of apoptosis by the soluble guanylyl cyclase/cGMP pathway in human ovarian cancer cells.
    Fraser M; Chan SL; Chan SS; Fiscus RR; Tsang BK
    Oncogene; 2006 Apr; 25(15):2203-12. PubMed ID: 16288207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance.
    Stiewe T; Haran TE
    Drug Resist Updat; 2018 May; 38():27-43. PubMed ID: 29857816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer: crime and punishment.
    Sharpless NE; DePinho RA
    Nature; 2005 Aug; 436(7051):636-7. PubMed ID: 16079829
    [No Abstract]   [Full Text] [Related]  

  • 19. Transient depletion of p53 followed by transduction of c-Myc and K-Ras converts ovarian stem-like cells into tumor-initiating cells.
    Motohara T; Masuko S; Ishimoto T; Yae T; Onishi N; Muraguchi T; Hirao A; Matsuzaki Y; Tashiro H; Katabuchi H; Saya H; Nagano O
    Carcinogenesis; 2011 Nov; 32(11):1597-606. PubMed ID: 21828057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The ubiquitin-proteasome system is inhibited by p53 protein expression in human ovarian cancer cells.
    Hwang IY; Baguley BC; Ching LM; Gilchrist CA
    Cancer Lett; 2010 Aug; 294(1):82-90. PubMed ID: 20153923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.